As filed with the Securities and Exchange Commission on January 29, 2015
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Spark Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 2836 | 46-2654405 | ||
(State or Other Jurisdiction of Incorporation or Organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
3737 Market Street
Suite 1300
Philadelphia, PA 19104
(888) 772-7560
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Jeffrey D. Marrazzo
Chief Executive Officer
Spark Therapeutics, Inc.
3737 Market Street
Suite 1300
Philadelphia, PA 19104
(888) 772-7560 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
Steven D. Singer, Esq. Lia Der Marderosian, Esq. Wilmer Cutler Pickering Hale and Dorr LLP 7 World Trade Center, 250 Greenwich Street New York, NY 10007 Telephone: (212) 230-8800 |
Joseph W. La Barge, Esq. General Counsel Spark Therapeutics, Inc. 3501 Civic Center Boulevard Philadelphia, PA 19104 Telephone: (888) 772-7560 |
Richard Truesdell, Jr., Esq. Sophia Hudson, Esq. Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 Telephone: (212) 450-4000 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ¨
If this Form is filed to register additional securities for an offering pursuant Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. x 333-201318
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer | ¨ | Accelerated filer | ¨ | |||
Non-accelerated filer | x (Do not check if a smaller reporting company) | Smaller reporting company | ¨ |
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of each class of securities to be registered |
Amount to be registered (1) |
Proposed maximum offering price per share (2) |
Proposed maximum aggregate offering price (2) |
Amount of registration fee | ||||
Common Stock, $0.001 par value per share |
575,000 shares | $23.00 | $13,225,000 | $1,537 | ||||
| ||||||||
|
(1) | Includes 75,000 shares of common stock the underwriters have the option to purchase. |
(2) | Calculated in accordance with Rule 457(a) of the Securities Act of 1933 solely on the basis of $23.00, the initial public offering price set forth on the cover page of the Registrants Prospectus dated January 29, 2015 relating to its initial public offering pursuant to the Companys Registration Statement on Form S-1 (File No. 333-201318). |
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This registration statement is being filed with respect to the registration of additional shares of common stock, par value $0.001 per share, of Spark Therapeutics, Inc., a Delaware corporation, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the earlier registration statement on Form S-1 (File No. 333-201318), which was declared effective by the Commission on January 29, 2015, are incorporated in this registration statement by reference.
The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Philadelphia, Commonwealth of Pennsylvania, on this 29th day of January, 2015.
Spark Therapeutics, Inc. | ||
By: | /s/ Jeffrey D. Marrazzo | |
Jeffrey D. Marrazzo | ||
Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.
Signature |
Title |
Date | ||
/s/ Jeffrey D. Marrazzo |
Director and Chief Executive Officer (Principal Executive Officer) |
January 29, 2015 | ||
Jeffrey D. Marrazzo |
||||
/s/ Stephen W. Webster |
Chief Financial Officer (Principal Financial and Accounting Officer) |
January 29, 2015 | ||
Stephen W. Webster | ||||
* |
Director | January 29, 2015 | ||
Katherine A. High, M.D. | ||||
* |
Director | January 29, 2015 | ||
Steven M. Altschuler, M.D. | ||||
* |
Director | January 29, 2015 | ||
A. Lorris Betz, M.D., Ph.D. | ||||
* |
Director | January 29, 2015 | ||
Lars Ekman, M.D., Ph.D. | ||||
* |
Director | January 29, 2015 | ||
Anand Mehra, M.D. | ||||
* |
Director | January 29, 2015 | ||
Vincent Milano | ||||
* |
Director | January 29, 2015 | ||
Elliott Sigal, M.D., Ph.D. |
* By: | /s/ Jeffrey D. Marrazzo | |
Jeffrey D. Marrazzo | ||
Attorney-in-Fact |
EXHIBIT INDEX
Exhibit |
Description | |
5 | Opinion of WilmerHale | |
23.1 | Consent of KPMG LLP | |
23.2 | Consent of WilmerHale (included in Exhibit 5) | |
24* | Powers of Attorney |
* | Filed as Exhibits 24.1 and 24. 2 to the Registrants Registration Statement on Form S-1 (File No. 333-201318) filed with the Commission on December 30, 2014 and January 20, 2015, respectively. |